1 / 16

Ri 藍 叡

Paper reading: Portal vein thrombosis - New insight into aetiology and management Aliment Pharmacol Ther 2005; 21: 1-9 - A concise review The American Journal of Gastroenterology Vol. 97, No. 3, 2002. Ri 藍 叡. Introduction.

titus
Download Presentation

Ri 藍 叡

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Paper reading:Portal vein thrombosis - New insight into aetiology and managementAliment Pharmacol Ther 2005; 21: 1-9- A concise review The American Journal of Gastroenterology Vol. 97, No. 3, 2002 Ri 藍 叡

  2. Introduction • Portal vein thrombosis (PVT) is an cause of pre-hepatic portal hypertension • At time it is idiopathic, although several predisposing conditions are known to exist • The management of PVT has perceived risks of anticoagulant therapy

  3. Aetiology • Voorhees et al. (1974), Webb et al. (1979): The majority of patients with PVT did not have underlying etiologies • Systemic thrombophilic factors • Inherited • Acquired • Local factors

  4. Pathogenesis • Cirrhosis: •  Portal blood flow •  Liver synthetic activity of protein C, S and antithrombin III • High incidence of concomitant HCC • Cancer: • Tumor invasion • Compression or constriction effect from tumor mass • Prothrombogenic changes (cysteine protease)

  5. Pocket Medicine the Massachusetts General Hospital Handbook of Internal Medicine, 2nd edition, 5-12

  6. Multiple factors contributing to the development of venous thrombosis~ Rosendaal FR. Lancet 1999 • At least one mutated thrombophilic gene was detected in 69.5% of the cirrhotic patients with PVT (Amitrano et al. Hepatology 2000) • Infant with infection of the umbilical vein in the absence of prothrombotic disorders infrequently go on to develop PVT (Valla et al. J Hepatol 2000) • Blunt trauma and surgical procedures, generally, do not precipitate PVT unless there is an associated prothrombotic state. (Eguhi et al. Arch Surg 1991)

  7. Clinical manifestations • No definitive time-frame distinguishes acute from chronic PVT (~ 60 days) • Acute PVT • Abdominal pain, N/V (Mesenteric veins involved) • Few clinical consequences : • Immediate vasodilation of the hepatic arterial system • Rapid development of tortuous collateral veins bypassing (cavernous transformation)

  8. Chronic PVT • Portal hypertension • Hemorrhage of Gastroesophageal varices, splenomegaly, hypersplenism • Ascites, jaundice, hepatoencephalopathy • Outcome of the bleeding is far better than the patient with cirrhosis • 10-year-survival was 81% without cirrhosis, cancer or mesenteric vein thrombosis (Janssen et al. Gut 2001)

  9. Investigation • Color doppler ultrasonography (CDUS) • Echogenic thrombus within portal vein lumen • Dilation proximal to the occlusion • Absence of an identifiable portal vein • Collateral vessels (cavernous transformation) • CT scan • Filling defect in contrast-enhanced lumen • Train track appearance when totally occluded • MR angiography • Portal venography • Endoscopic ultrasound

  10. Management • Reverse or prevent the advancement of thrombosis • Treat the complications

  11. Reverse or prevent the advancement of thrombosis • Acute/ recent-onset • Anticoagulation may result in recanalization in more than 80% of cases (Condat et al. Hepatology 2000) • High rates of recanalization with thrombolysis compared with consevative treatment (Malkowski et al. Hepatogastroenterology 2003) • Role of transjugular intrahepatic porto-systemic shunt (TIPSS) insertion • Anticoagulation fails • Endoscopic therapies are effective

  12. Reverse or prevent the advancement of thrombosis • Chronic • the risk of thrombosis is currently as clinically significant as the risk of bleeding. The benefit-risk ratio favors anticoagulant therapy (Condat et al. Gastroenterology 2001) • Cohort study with 136 patients, 84 received anticoagulants, followed for median of 46 months.

  13. Management • Reverse or prevent the advancement of thrombosis • Treat the complications • no studies about bleeding complications in patient with PVT • Primary prophylaxis: beta-blockade • Secondary prophylaxis: beta-blockade + endoscopic therapy

  14. Take home message • Multiple risk factors are involved in the majority of cases • The prognosis from variceal bleeding in non-cirrhotic patients with PVT is good • In patients with acute PVT, the efficacy of thrombolytic therapy has been demonstrated • In patients with chronic PVT, risks of anticoagulation therapy may be overstated. Risk of thrombus extension, as mesenteric infarction is an important cause of death

  15. Thanks!

More Related